TrialJournal of molecular medicine (Berlin, Germany)2010

Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.

Giovanni Mantovani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.